HN 표시: SubstanceWiki – 향정신성 물질에 대한 오픈 소스 백과사전

SubstanceWiki is a comprehensive, evidence-based encyclopedia of psychoactive substances — covering dosage guides, subjective effects, combinations, comparisons, drug interactions, and harm reduction practices. Free and open-source. Indole alkaloids · Stimulants, Opioids Kratom (*Mitragyna speciosa*) is a tropical evergreen tree in the coffee family (Rubiaceae), native to the rainforests of Thailand, Malaysia, Indonesia, Myanmar, and Papua New Guinea. For centuries, Southeast Asian laborers, farmers, and fishermen have chewed its dark, glossy leaves or brewed them into tea to fight fatigue, dull the aches of physical labor, and lift their spirits through long working days. In the West, kratom has exploded in popularity since the 2000s, becoming one of the most widely used unregulated psychoactive botanicals in the United States, with an estimated 10 to 16 million regular users as of 2024. What makes kratom pharmacologically fascinating is its dose-dependent duality. At low doses (1-3 grams of dried leaf), it behaves like a stimulant: users describe increased energy, improved focus, and a warm sociability reminiscent of a strong cup of coffee but with a distinctly euphoric edge. At higher doses (5-8+ grams), the experience shifts decisively into opioid territory: pain relief, sedation, and a thick, contented warmth that users compare to low-dose hydrocodone. This dual personality arises from the complex receptor pharmacology of its primary alkaloids, mitragynine and 7-hydroxymitragynine, which act as partial agonists at mu-opioid receptors while also engaging adrenergic and serotonergic systems. Kratom is the only plant besides the opium poppy (*Papaver somniferum*) known to produce alkaloids that activate mu-opioid receptors. But unlike classical opioids, mitragynine is a partial agonist with G-protein biased signaling, which appears to create a ceiling effect on respiratory depression -- the mechanism responsible for the vast majority of opioid overdose deaths. This pharmacological distinction is central to the fierce debate surrounding kratom: advocates point to its potential as a harm reduction tool for people managing chronic pain or transitioning away from more dangerous opioids, while regulatory agencies like the FDA have raised concerns about dependence, product contamination, and the lack of quality control in the unregulated market. The political landscape around kratom is remarkably active. The DEA attempted to schedule kratom in 2016 but withdrew its proposal after over 140,000 public comments and a letter from 51 members of Congress -- the first time the agency had ever reversed a scheduling action due to public opposition. As of 2026, kratom remains federally unscheduled in the US, though six states ban it outright and over 20 have enacted Kratom Consumer Protection Acts to regulate rather than prohibit it. Meanwhile, Thailand re-legalized kratom in 2021 after decades of prohibition, granting amnesty to over 12,000 previously convicted individuals. Tryptamine · Psychedelic Psilocybin mushrooms — known colloquially as magic mushrooms, shrooms, or simply mushies — are fungi containing the psychedelic tryptamines psilocybin and psilocin. Over 200 species across multiple genera produce these compounds, with *Psilocybe cubensis* being the most widely cultivated and *Psilocybe semilanceata* (liberty caps) the most commonly encountered wild species in temperate climates. Upon ingestion, psilocybin is rapidly dephosphorylated into psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors, producing profound shifts in perception, emotion, and cognition that typically last four to six hours. What sets psilocybin mushrooms apart from synthetic psychedelics is their character. Users consistently describe the experience as warmer, more emotionally textured, and more "organic" than LSD or research chemicals. The mushroom trip tends to feel like a conversation — sometimes gentle, sometimes confrontational — rather than a ride. This quality has made them central to spiritual and ceremonial use for thousands of years, and it is part of why the modern psychedelic research renaissance has placed psilocybin at its center. The clinical data is now substantial. Landmark trials at Johns Hopkins, NYU, and Imperial College London have demonstrated significant, lasting antidepressant effects from just one or two supervised psilocybin sessions. A 2024 dose-response meta-analysis of randomized controlled trials confirmed psilocybin's efficacy for major depressive disorder, including treatment-resistant cases. Over 134 clinical trials are now registered on ClinicalTrials.gov across 54 potential therapeutic indications — depression, end-of-life anxiety, addiction, OCD, eating disorders, cluster headaches, and more. Oregon legalized supervised psilocybin therapy in 2020, Colorado followed in 2022, and dozens of cities have decriminalized personal possession. From a safety standpoint, psilocybin mushrooms have o